Story
Summit Therapeutics Rallies After Jefferies Upgrade to 'Buy' on Drug Trial Optimism
Shares of Summit Therapeutics (NASDAQ: SMMT) jumped 5.8% in pre-market trading on Wednesday after analysts at Jefferies upgraded the stock, citing growing optimism over upcoming clinical trial results for the company's lead drug candidate.
Upgrade Details and Price Target
Jefferies raised its rating on Summit Therapeutics to 'Buy' from a previous 'Hold' designation. The investment bank also significantly increased its price target on the stock to $25 from $15.
The upgrade comes ahead of a key data release anticipated by the end of 2026, which the firm views as a major potential catalyst for the biopharmaceutical company's valuation.
Confidence in Ivonescimab Data
In a note to clients, Jefferies analyst Faisal Khurshid expressed confidence that the upcoming progression-free survival (PFS) data from the H3 trial is "highly likely to be statistically significant." The analyst's conviction is based on an analysis of the trial's statistical plan and a comparison between data from China and the global study.
AdJefferies projects a hazard ratio (HR) for PFS in the range of 0.65 to 0.70, a result that would be considered successful. The firm believes such an outcome would also signal a high probability of positive overall survival (OS) data, which is expected in the first half of 2027.
Broader Trial Success
Khurshid noted that Jefferies holds "strong conviction" in the drug's mechanism of action, bolstered by previously announced positive overall survival results from the H6, H2, and H-GI1 trials.
The firm believes that ivonescimab's potential as a first-in-class treatment will continue to be a primary driver of its value. Summit Therapeutics focuses on developing innovative medicines for patients with unmet medical needs.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.